Meeting Coverage:

American Academy of Ophthalmology

AAO: 2018

Anatomy in HAWK and HARRIER

Show Description +

Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the 48-week data, focusing in particular on anatomic results.

Posted: 10/09/2018

Up Next


New IOL Technologies

Amr M. Kouchouk, MD, Kendall E. Donaldson, MD, MS, Vance M. Thompson, MD, FACS

Topical Retina Treatments

Carl D. Regillo, MD, FACS, Caroline R. Baumal, MD, Michael A. Singer, MD

Refractive Residencies

George O. Waring IV, MD, FACS , Osama Ibrahim, MD, Renato Ambrosio Jr, MD, PhD

Take-Home Points for APL-2

David S. Boyer, MD

Customizing the IOL

George O. Waring IV, MD, FACS

Anatomy in HAWK and HARRIER

Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the 48-week data, focusing in particular on anatomic results.

Posted: 10/09/2018


Please log in to leave a comment.

More From AAO: 2018 Coverage

New IOL Technologies

Amr M. Kouchouk, MD, Kendall E. Donaldson, MD, MS, Vance M. Thompson, MD, FACS